Close

Orphazyme (ORPH) has received CRL from the FDA following its review of the new drug application for arimoclomol

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. SPOT
3. SPY
4. GM
5. SHW
6. AMZN
7. MSCI
8. NVDA
9. IBM
10. AAPL


Go back to Orphazyme (ORPH) has received CRL from the FDA following its review of the new drug application for arimoclomol

Orphazyme A/S (ORPH) Sinks 54% on CRL

June 18, 2021 6:56 AM EDT

Orphazyme A/S (NASDAQ: ORPH) sinks 54% in pre-open trading announced it has... More